Konverge (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxomil blocks the angiotensin II type 1 (AT1) receptor, preventing the hormone angiotensin II from causing vasoconstriction and stimulating aldosterone release. This results in relaxed blood vessels, reduced fluid retention, and ultimately lower blood pressure.

The dosage of Konverge is determined by the prescribing clinician based on the patient’s blood pressure, response to therapy, and overall health status. The prescriber will select the appropriate strength and dosing schedule for each individual.

The safety of Konverge in pregnancy or while nursing has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and decisions should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Konverge offers a dual‑mechanism approach by combining an angiotensin II receptor blocker with a calcium channel blocker, which can provide more consistent blood pressure control than monotherapy. Compared with separate tablets, the fixed‑dose combination may improve adherence and simplify treatment regimens.

Konverge should be stored at ambient temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Konverge is taken orally, usually once daily, with or without food. Swallow the tablet whole with a glass of water. Patients should follow the dosing instructions provided by their prescriber and not alter the regimen without medical advice.

Serious adverse events, although rare, can include angioedema, severe hypotension, acute renal impairment, and significant liver enzyme elevations. Patients should seek immediate medical attention if they experience swelling of the face or throat, dizziness, fainting, or signs of liver dysfunction.

Konverge is contraindicated in patients with known hypersensitivity to olmesartan, amlodipine, or any component of the formulation. It should also be avoided in individuals with severe hepatic impairment and in those taking aliskiren concomitantly if they have diabetes or renal impairment.